Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

ASE gears up for 2.5D, 3D IC commercialization

September 9, 2010 10:34 am | by I-Micronews | News | Comments

3D IC Technology holds great promise for manufacturing at 20nm and beyond, bridging the gap between SoC and future system requirements.

TOPICS:

STATS ChipPAC achieves major milestone of over 35 million eWLB units shipped

September 9, 2010 10:33 am | by I-Micronews | News | Comments

STATS ChipPAC Ltd. ("STATS ChipPAC" or the "Company") (SGX-ST: STATSChP), a leading semiconductor test and advanced packaging service provider, today announced it has achieved a major industry milestone in the volume ramp of embedded Wafer-Level Ball Grid Array (eWLB) technology with more...

Industrial Real Estate Shows Signs of Recovery in the United States

September 9, 2010 10:33 am | by Material Handling Industry of America | News | Comments

The North American Industrial real estate sector has delivered positive news for the second quarter 2010, according to a national report by Jones Lang LaSalle. National average vacancy rates have tumbled 20 basis points for the first time in almost two

Advertisement

FDA: New Warnings Required on Use of Gadolinium-Based Contrast Agents

September 9, 2010 10:32 am | by Bio-Medicine.Org | News | Comments

SILVER SPRING, Md., Sept. 9 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration is requiring that gadolinium-based contrast agents (GBCAs) carry new warnings on their labels about the risk of a rare and potentially fatal condition known as nephrogenic systemic fibrosis (NSF),...

TOPICS:

Improvement in Prediction of Blood Clots in Cancer Patients

September 9, 2010 10:32 am | by Bio-Medicine.Org | News | Comments

WASHINGTON, Sept. 9 /PRNewswire-USNewswire/ -- For cancer patients, who have an increased risk of developing venous thromboembolism (VTE) due to a hyperactive blood coagulation system, there is now an enhanced risk model to predict their chance of developing blood clots, according to a...

TOPICS:

Blood Donors Needed as School, Fall Season Returns

September 9, 2010 10:32 am | by Bio-Medicine.Org | News | Comments

NEW YORK, Sept. 9 /PRNewswire-USNewswire/ -- New York Blood Center (NYBC), serving more than 20 million people in New York City, Long Island, the Hudson Valley and New Jersey, calls upon our communities to please donate blood, after last week's stormy weather and Labor Day holiday weekend...

TOPICS:

Detailed Cholesterol Test Provides Vital Clues for Women in Search of PCOS Answers

September 9, 2010 10:32 am | by Bio-Medicine.Org | News | Comments

BIRMINGHAM, Ala., Sept. 9 /- Polycystic Ovarian Syndrome, known as PCOS, is a silent and often mysterious disease that plays havoc with a woman's body and increases the risk of serious illness. PCOS is the number one cause of female infertility and increases the risk of heart disease,...

TOPICS:

Luminex Corporation to Present at UBS Global Life Sciences Conference

September 9, 2010 10:31 am | by Bio-Medicine.Org | News | Comments

AUSTIN, Texas, Sept. 9 /- Luminex Corporation (Nasdaq: LMNX ) today announced that management will present at UBS Global Life Sciences Conference to be held September 20 - 22, 2010, in New York City, New York. (Logo:   http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) (Logo:...

TOPICS:
Advertisement

Newcastle University and ISAEC to research genetics of drug induced liver injury

September 9, 2010 8:35 am | by EurekAlert | News | Comments

(Edelman Public Relations) The International Serious Adverse Events Consortium (SAEC) announced today it will collaborate with Newcastle University to research the genetics of drug induced liver injury. The SAEC is a novel, non-profit international research consortium, formed by...

TOPICS:

University of Liverpool and ISAEC to research genetics of drug-induced hypersensitivity reactions

September 9, 2010 8:35 am | by EurekAlert | News | Comments

(Edelman Public Relations) The International Serious Adverse Events Consortium (SAEC) announced today it will collaborate with The University of Liverpool to research the genetics of a form of serious adverse drug reaction called hypersensitivity. These are thought to involve the...

TOPICS:

Aging drug users are increasing and facing chronic physical and mental health problems

September 9, 2010 8:35 am | by EurekAlert | News | Comments

(Wiley-Blackwell) Health and social services are facing a new challenge, as many illicit drug users get older and face chronic health problems and a reduced quality of life. Researchers interviewed people aged 49-61 in contact with voluntary sector drug treatment services. The...

TOPICS:

Anchor Therapeutics licensing deal to net up to $480M

September 9, 2010 8:34 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Cambridge biotech Anchor Therapeutics Inc. stands to receive up to $480 million from New Jersey-based Ortho-McNeil Janssen Pharmaceuticals Inc., related to a collaborative research and licensing deal associated with Anchor’s pepducin technology.

New Study: Physician Adoption of Live Video Detailing Has Doubled Since 2008, But Will Likely Plateau Until 2012 as Pharma Optimizes Targeting

September 9, 2010 8:34 am | by Bio-Medicine.Org | News | Comments

NEW YORK, Sept. 9 /- Live video detailing has made a strong comeback after a false start in the early 2000s, according to pharmaceutical and healthcare market research company Manhattan Research's ePharma Physician ® v10.0 study. Physician adoption of live video detailing has more...

TOPICS:

Medizone International Files For Additional Bio-Terrorism Countermeasures Patent Protection

September 9, 2010 8:34 am | by Bio-Medicine.Org | News | Comments

SAN FRANCISCO, Sept. 9 /- Medizone International, Inc. (OTC Bulletin Board, OTCQB: MZEI) announces it has filed an additional international patent application covering recent developments in its variant of AsepticSure™ designed for government use in bio-terrorism countermeasures....

TOPICS:

Misonix Announces New Distribution Agreement For Spain

September 9, 2010 8:33 am | by Bio-Medicine.Org | News | Comments

FARMINGDALE, N.Y., Sept. 9 /- Misonix, Inc. (Nasdaq: MSON ), a developer of state of the art, ultrasonic medical device technology, which worldwide is used for acute health conditions, has entered into a new, three year, exclusive distribution agreement with Dismeval, s.l.,  based in...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading